Literature DB >> 30336494

Lafora Disease: A Review of Molecular Mechanisms and Pathology.

Brandy Verhalen1, Susan Arnold2, Berge A Minassian1,2.   

Abstract

Lafora's disease is a neurodegenerative disorder caused by recessive loss-of-function mutations in the EPM2A (laforin glycogen phosphatase) or EPM2B (malin E3 ubiquitin ligase) genes. Neuropathology is characterized by malformed precipitated glycogen aggregates termed Lafora bodies. Asymptomatic until adolescence, patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade. Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen's solubility. Significant gaps remain in precise mechanistic understanding. However, demonstration that partial reduction in brain glycogen synthesis near-completely prevents the disease in its genetic animal models opens a direct present path to therapy. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 30336494      PMCID: PMC6748624          DOI: 10.1055/s-0038-1675238

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  26 in total

1.  Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.

Authors:  Anna A DePaoli-Roach; Vincent S Tagliabracci; Dyann M Segvich; Catalina M Meyer; Jose M Irimia; Peter J Roach
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Glycogen hyperphosphorylation underlies lafora body formation.

Authors:  Julie Turnbull; Peixiang Wang; Jean-Marie Girard; Alessandra Ruggieri; Tony J Wang; Arman G Draginov; Alexander P Kameka; Nela Pencea; Xiaochu Zhao; Cameron A Ackerley; Berge A Minassian
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

3.  Phosphate incorporation during glycogen synthesis and Lafora disease.

Authors:  Vincent S Tagliabracci; Christian Heiss; Chandra Karthik; Christopher J Contreras; John Glushka; Mayumi Ishihara; Parastoo Azadi; Thomas D Hurley; Anna A DePaoli-Roach; Peter J Roach
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

4.  Lafora bodies in skeletal muscle are fiber type specific.

Authors:  J Turnbull; J-M Girard; N Pencea; X Zhao; T E Graham; P Wang; C A Ackerley; B A Minassian
Journal:  Neurology       Date:  2011-03-30       Impact factor: 9.910

5.  A pilot study of a ketogenic diet in patients with Lafora body disease.

Authors:  Simonetta Cardinali; Laura Canafoglia; Simona Bertoli; Silvana Franceschetti; Giovanni Lanzi; Anna Tagliabue; Pierangelo Veggiotti
Journal:  Epilepsy Res       Date:  2006-02-28       Impact factor: 3.045

6.  Nonepileptic visual hallucinations in Lafora disease.

Authors:  D M Andrade; J M del Campo; E Moro; B A Minassian; R A Wennberg
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

7.  Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates.

Authors:  Carolyn A Worby; Matthew S Gentry; Jack E Dixon
Journal:  J Biol Chem       Date:  2006-08-10       Impact factor: 5.157

Review 8.  Glycogen and its metabolism.

Authors:  Peter J Roach
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

9.  Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.

Authors:  Vincent S Tagliabracci; Jean Marie Girard; Dyann Segvich; Catalina Meyer; Julie Turnbull; Xiaochu Zhao; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

10.  Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer
Journal:  Nat Genet       Date:  2003-09-07       Impact factor: 38.330

View more
  8 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Malin restoration as proof of concept for gene therapy for Lafora disease.

Authors:  Olga Varea; Joan J Guinovart; Jordi Duran
Journal:  Brain Commun       Date:  2022-06-23

3.  Molecular architecture of the glycogen- committed PP1/PTG holoenzyme.

Authors:  Marta Stefania Semrau; Gabriele Giachin; Sonia Covaceuszach; Alberto Cassetta; Nicola Demitri; Paola Storici; Graziano Lolli
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

4.  Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung Cancers.

Authors:  Ramon C Sun; Vikas V Dukhande; Zhengqiu Zhou; Lyndsay E A Young; Shane Emanuelle; Christine Fillmore Brainson; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-09-12       Impact factor: 27.287

5.  Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Authors:  Luca Vignatelli; Francesca Bisulli; Federica Pondrelli; Lorenzo Muccioli; Laura Licchetta; Barbara Mostacci; Corrado Zenesini; Paolo Tinuper
Journal:  Orphanet J Rare Dis       Date:  2021-08-16       Impact factor: 4.123

6.  An empirical pipeline for personalized diagnosis of Lafora disease mutations.

Authors:  M Kathryn Brewer; Maria Machio-Castello; Rosa Viana; Jeremiah L Wayne; Andrea Kuchtová; Zoe R Simmons; Sarah Sternbach; Sheng Li; Maria Adelaida García-Gimeno; Jose M Serratosa; Pascual Sanz; Craig W Vander Kooi; Matthew S Gentry
Journal:  iScience       Date:  2021-10-13

Review 7.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

8.  Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity.

Authors:  Olga Varea; Jordi Duran; Mònica Aguilera; Neus Prats; Joan J Guinovart
Journal:  Neurobiol Dis       Date:  2020-11-07       Impact factor: 5.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.